AGER and diabetic kidney disease: Apixaban could inhibit the crosstalk of the AGE-RAGE axis with the thrombin-PAR-1/factor Xa-PAR-2 system in the diabetic kidneys, thereby suppressing the progression of experimental diabetic nephropathy.